AR882 (Pozdeutinurad)

About Arthrosi Therapeutics

Arthrosi Therapeutics is a private, clinical-stage biotech company advancing its lead candidate, AR882 (pozdeutinurad), a next-generation urate transporter 1 (URAT1) inhibitor, through pivotal Phase 3 trials for gout and tophaceous gout. The company has demonstrated strong execution, completing Phase 3 enrollment ahead of schedule and securing a substantial $153 million Series E financing in late 2025. In a major strategic development, Arthrosi has entered into an agreement to be acquired by Swedish Orphan Biovitrum (Sobi), which will provide the resources and global reach to potentially bring AR882 to market.

Therapeutic Areas